BC Innovations | Oct 31, 2018
Distillery Therapeutics


INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...
BC Innovations | Feb 1, 2018
Translation in Brief

Cloning closer to home

Chinese Academy of Sciences researchers showed epigenetic modification is key for successful cloning of cynomolgus monkeys, overcoming the technical hurdles that have stalled the generation of live non-human primates despite success in 23 other mammalian...
BC Innovations | May 8, 2017
Distillery Techniques


TECHNOLOGY: Tool compounds Three cyclic peptide-based inhibitors of KDM4A , KDM4B and KDM4C could be useful for probing the role of the enzymes in cancer. Screening of a library of thioether-based macrocycles in vitro identified three...
BC Innovations | Dec 10, 2015
Distillery Techniques

Techniques: Patient-specific embryonic stem cell (ESC) lines created by somatic cell nuclear transfer and overexpression of lysine-specific demethylase 4A (KDM4

Disease models KDM4A lysine-specific demethylase 4A JMJD2A Harvard Medical School...
BC Innovations | Feb 6, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Lysine-specific demethylase 4 (KDM4; JMJD2); lysine-specific demethylase 1A (KDM1A; LSD1) SAR studies suggest compounds that inhibit both LSD1 and JMJD2 could be useful for...
BC Innovations | Jan 31, 2013
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Herpes simplex virus (HSV); cytomegalovirus (CMV) Lysine-specific demethylase 4 (KDM4; JMJD2) Cell culture and explanted mouse ganglia studies suggest JMJD2 inhibitors could be used...
Items per page:
1 - 6 of 6